Stockscreener 앱 받기
31.31
3.39%
1.19
시간 외 거래:
31.31
전일 마감가:
$30.12
열려 있는:
$29.93
하루 거래량:
38,770
Relative Volume:
0.54
시가총액:
$123.80M
수익:
$36.84M
순이익/손실:
$-729.00K
주가수익비율:
-33.90
EPS:
-0.9237
순현금흐름:
$-10.02M
1주 성능:
-9.19%
1개월 성능:
-5.29%
6개월 성능:
-15.66%
1년 성능:
+101.68%
1일 변동 폭
$29.48
$31.42
1주일 범위
$28.76
$36.52
52주 변동 폭
$14.55
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
31.31 | 119.09M | 36.84M | -729.00K | -10.02M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2026-01-05 | 개시 | TD Cowen | Buy |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
The Technical Signals Behind (VTVT) That Institutions Follow - Stock Traders Daily
vTv Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Lowers Earnings Estimates for vTv Therapeutics - marketbeat.com
vTv Therapeutics Inc (VTVT) Reports Q2 Loss of $1.05 Per Share -- What Does a GF Score of 26/100 Indicate? - GuruFocus
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen - marketbeat.com
H.C. Wainwright Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
vTv Therapeutics Inc (VTVT) Stock News Today - TradingKey
vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - kalkine.com.au
vTv Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
vTv Therapeutics (VTVT) Advances Diabetes Treatment Amid High Pr - GuruFocus
VTVT Maintains Buy Rating -- Price Target Lowered to $42.00 by H - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright - MarketBeat
VTv Therapeutics: Q2 Earnings Snapshot - marketscreener.com
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - manilatimes.net
VTV THERAPEUTICS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $42 FROM $45 - Bitget
VTVT Q2'26 Earnings: revenue estimate is 333.33K USD - TradingView
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Precision Trading with Vtv Therapeutics Inc. (VTVT) Risk Zones - Stock Traders Daily
vTv Therapeutics (VTVT) Edges Down 1% to $32.35, Holding Gains Above Key SupportMotive Wave - dars.gov.et
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageHere's What Happened - marketbeat.com
vTv Therapeutics Inc. Revenue Breakdown – NASDAQ:VTVT - TradingView
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics (VTVT): Millennium entities disclose 6.9% ownership of Class A shares - Stock Titan
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
vTv Therapeutics Grants Employees Options With 4-Year Vesting - Stock Titan
vTv Therapeutics Inc (VTVT) Cash Flow - TradingKey
vTv Therapeutics Inc (VTVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
vTv Therapeutics Inc (VTVT) Balance Sheet - TradingKey
vTv Therapeutics Inc (VTVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VTVT|vTv Therapeutics Inc|Price:31.030|Chg%:+0.300 - TradingKey
vTv Therapeutics Inc (VTVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
vTv Therapeutics Inc (VTVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
vTv Therapeutics (VTVT) Fades 2.9% as Cautious Trading Prevails Near Key ResistanceWeak Sell Signals - dars.gov.et
vTv Therapeutics, Inc. Class A Revenue Breakdown – SWB:5VT0 - TradingView
TradingKey - TradingKey
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Technical Reactions to VTVT Trends in Macro Strategies - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT) - The Globe and Mail
VTVT Maintains Buy Rating by BTIG -- Price Target Raised to $57. - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
MSN Money - MSN
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Recurring Items, Stock DeclinesRevenue Guidance Range - DonanımHaber
vTv Therapeutics lures two employees with 12,500 stock options - Stock Titan
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay - The Globe and Mail
Trading the Move, Not the Narrative: (VTVT) Edition - Stock Traders Daily
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating - Investing.com
Enterprise value to EBITDA forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.20%
0.07%
자본화:
|
볼륨(24시간):